Eosinophils in the network of chemokines;Eosinophile granulozyten im netzwerk der chemokine

Allergologie

Volumn 24, Issue 9, 2001, Pages 368-389

  Elsner, J ^a   Kapp, A ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Antagonists; Chemokines; Eosinophils; Therapy

Indexed keywords

ALPHA CHEMOKINE; BETA CHEMOKINE; CX3C CHEMOKINE; GAMMA CHEMOKINE;

CELL ACTIVATION; CELL FUNCTION; CELL MIGRATION; EOSINOPHIL; IMMUNE RESPONSE; INFLAMMATION; MEDIATOR RELEASE; REVIEW;

EID: 0034805107     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (170)

1. Early modifications of chemokine production and mRNA expression during rush venom immunotherapy
2. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates
3. Chemokine release from activated human dermal microvascular endothelial cells - Implications for the pathophysiology of scleroderma?
4. Assessment of chemokine receptor expression by human Th1 and Th2 cells in vitro and in vivo
5. T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure
6. A small-molecule, non-peptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
7. Chemokines and leukocyte traffic
8. Blocking chemokine receptors
9. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells
10. Human dermal fibroblasts express eotaxin: Molecular cloning, mRNA expression and identification of eotaxin sequence variants
11. A new class of membrane-bound chemokine with a CX3C motif
12. Cutaneous injection of RANTES causes eosinophil recruitment: Comparison of non-allergic and allergic human subjects
13. CCR3 blockade as a new therapy for asthma
14. Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-3D10
15. Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI)
16. Regulatory mechanisms that modulate signalling by G protein-coupled receptors
17. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s
18. Up-regulation of CCR1 and CCR3 and induction of chemotaxis to CC chemokines by IFN-gamma in human neutrophils
19. Calcium gradients underlying polarization and chemotaxis of eosinophils
20. Eosinophils in asthma
21. The chemokine/chemokine receptor family: Potential and progress for therapeutic intervention
22. Cloning and functional expression of a human eosinophil CC chemokine receptor
23. CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein-1-alpha, interleukin-8 and RANTES
24. Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis
25. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease
26. Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation
27. Cellular polarization induced by chemokines: A mechanism for leukocyte recruitment
28. Natural proteolytic processing of hemofiltrate CC chemokine 1 generates a potent CC chemokine receptor (CCR) 1 and CCR5 agonist with anti-HIV properties
29. Chemotaxis in eukaryontic cells: A focus on leukocytes and dictyostelium
30. Expression of RANTES in biopsies of skin and upper gastrointestinal tract from patients with systemic sclerosis
31. Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils
32. Actin polymerization in human eosinophils, unlike human neutrophils, depends on intracellular calcium mobilization
33. Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes
34. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils
35. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils
36. Regulation and modulation of eosinophil effector functions
37. Activation of human eosinophils by chemokines
38. Aktivierung und modulation eosinophiler granulozyten durch chemokine: Ihre bedeutung für die allergische entzündung
39. Immunological aspects of allergic inflammation: Eosinophils
40. Differential activation of CC chemokine receptors by AOP-RANTES
41. C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils
42. Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti-C5a receptor (CD88) antibodies
43. The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3
44. The CC chemokine receptor antagonist Met-RANTES inhibits eosinophil effector functions
45. Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils
46. Characterization of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma
47. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes
48. Chemokine production by the BEAS-2B human bronchial epithelial cells: Differential regulation of eotaxin, IL-8, and RANTES by TH2- and TH1-derived cytokines
49. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia
50. Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils
51. The biology of the eosinophilic eosinophitic leukocyte
52. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionallly critical NH2-terminal residues
53. The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation into the lung in vivo
54. Cell adhesion: The molecular basis of tissue architecture and morphogenesis
55. Interferon-gamma up-regulates CCR5 expression in cord and adult blood mononuclear phagocytes
56. Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody
57. Genomic organization, sequence analysis and transcriptional regulation of the human MCP-4 chemokine gene (SCYA13) in dermal fibroblasts: A comparison to other eosinophilic beta-chemokines
58. Identification and characterization of small molecule functional antagonists of the CCR1 chemokine receptor
59. The CC chemokine receptor 3 CCR3 is functionally expressed on eosinophils but not on neutrophils
60. Chemokine receptor antagonists
61. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia
62. Eotaxin activates T cells to chemotaxis and adhesion only if induced to express CCR3 by IL-2 together with IL-4
63. Eotaxin: Cloning of an eosinophil chemoattractant cytokine and increased mRNA expression in allergen-challenged guinea-pig lungs
64. Eotaxin: A potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation
65. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils
66. The role of eosinophils in the pathogenesis of atopic dermatitis - Eosinophil granule proteins as markers of disease activity
67. The chemokine RANTES is more than a chemoattractant: Characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF
68. Shape changes, exocytosis, and cytosolic free calcium changes in stimulated eosinophils
69. Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3
70. Molecular cloning of a novel human CC chemokine (eotaxin-3) that is a functional ligand of CC chemokine receptor 3
71. Endocytosis and recycling of G protein-coupled receptors
72. Intracellular localization of interleukin-6 in eosinophils from atopic asthmatics and effects of interferon-gamma
73. Modulating chemokines: More lessons from viruses
74. Cell migration: A physically integrated molecular process
75. Cutaneous injection of human subjects with macrophage inflammatory protein-1-alpha induces significant recruitment of neutrophils and monocytes
76. Human eosinophils regulate human
77. The production of macrophage inflammatory protein-1-alpha by human basophils
78. Species selectivity of a small molecule antagonist for the CCR 1 chemokine receptor
79. CCR5 is characteristic of Th1 lymphocytes letter
80. Chemokines - Chemotactic cytokines that mediate inflammation
81. Aminooxypentane RANTES induces CCR5 internalization but inhibits recycling: A novel inhibitory mechanism of HIV infectivity
82. Fibroblasts but not epithelial cells obtained from human nasal mucosa produce the chemokine RANTES
83. Actin-based cell motility and cell locomotion
84. Dendritic cells produce macrophage inflammatory protein-1-gamma, a new member of the CC chemokine family
85. Expression of CXCR4 in eosinophils: Functional analyses and cytokine-mediated regulation
86. Eosinophil adhesion to vascular cell adhesion molecule-1 activates superoxide anion generation
87. Intracellular localization and release of eotaxin from normal eosinophils
88. Role of vascular cell adhesion molecule 1/very late activation antigen 4 and intercellular adhesion molecule 1/lymphocyte function-associated antigen 1 interactions in antigen-induced eosinophil and T cell recruitment into the tissue
89. C-C chemokine receptor 3 antagonism by the beta-chemokine macrophage inflammatory protein 4, a property strongly enhanced by an amino-terminal alanine-methionine swap
90. Polarization of chemokine receptors to the leading edge during lymphocyte chemotaxis
91. Assignment of the human CC chemokine MPIF-2/eotaxin-2 (SCYA24) to chromosome 7q11.23
92. Identification of an N-terminally truncated form of the chemokine RANTES and granulocyte-macrophage colony-stimulating factor as major eosinophil attractants released by cytokine-stimulated dermal fibroblasts
93. Cell-specific expression of RANTES, MCP-1, and MIP-1-alpha by lower airway epithelial cells and eosinophils infected with respiratory syncytial virus
94. Regulation of the receptor specificity and function of the chemokine RANTES (regulated on activation, normal T cell-expressed and secreted) by dipeptidyl peptidase IV- (CD26) mediated cleavage
95. Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow
96. A novel chemokine ligand for CCR10 and CCR3 expressed by epithelial cells in mucosal tissues
97. Characterization of the CC chemokine receptor 3 on human keratinocytes
98. The biologic role of interleukin-8: Functional analysis and expression of CXCR1 and CXCR2 on human eosinophils
99. Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils
100. The source and role of RANTES in interstitial lung disease
101. Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils
102. Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils
103. Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV. Conversion of RANTES into a potent inhibitor of monocyte chemotaxis and HIV-1-infection
104. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: Identification of MCP-2(6-76) as a natural chemokine inhibitor
105. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist
106. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions
107. Chemokine receptor antagonism as a new therapy for multiple sclerosis
108. Eosinophil development and bone marrow and tissue eosinophils in atopic asthma
109. Eosinophil-fibroblast interactions - Granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production
110. Dual pathways of internalization of the cholecystokinin receptor
111. Chemokines
112. Tryptase-chymase double-positive human mast cells express the eotaxin receptor CCR3 and are attracted by CCR3-binding chemokines
113. The Th1/Th2 paradigm
114. Characterization of the eosinophil granule proteins recognized by the activation-specific antibody EG2
115. A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry
116. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes
117. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells
118. Leukocyte polarization in cell migration and immune interactions
119. Cyclophosphamide-induced blood and tissue eosinophilia in contact sensitivity: Mechanism of hapten-induced eosinophil recruitment into the skin
120. Bidirectional signaling between the cytoskeleton and integrins
121. The role of chemokines in cutaneous allergic inflammation
122. HCC-1, a novel chemokine from human plasma
123. A novel human CC chemokine, eotaxin-3, which is expressed in IL-4-stimulated vascular endothelial cells, exhibits potent activity toward eosinophils
124. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety
125. Increased coexpression of eotaxin and interleukin-5 in bullous pemphigoid
126. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist
127. Chemokine and cytokine cooperativity: Eosinophil migration in the asthmatic response
128. Functional design in the actin cytoskeleton
129. Receptor-mediated endocytosis of CC chemokines
130. Detection of the chemokine RANTES in cytokine-stimulated human dermal fibroblasts
131. Virally encoded chemokines and chemokine receptors: Genetic embezzlement of host DNA
132. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor
133. CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3
134. Synergistic induction of MCP-1 and -2 by IL-1-beta and interferons in fibroblasts and epithelial cells
135. Eosinophil adhesion to nasal polyp endothelium is P-selectin-dependent
136. Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis
137. Chemokine-induced eosinophil recruitment. Evidence of a role for endogenous eotaxin in an in vivo allergy model in mouse skin
138. Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts
139. Differential chemokine expression in tissues involved by Hodgkin's disease: Direct correlation of eotaxin expression and tissue eosinophilia
140. The role of chemokines in Hodgkin's disease
141. Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes
142. High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, mcp-4, and other chemokines
143. Induction of monocyte chemotactic proteins MCP-1 and MCP-2 in human fibroblasts and leukocytes by cytokines and cytokine inducers. Chemical synthesis of MCP-2 and development of a specific RIA
144. Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin's disease, allowing for known prognostic factors
145. Chemokines and T lymphocytes: More than an attraction
146. Chemokines: Understanding their role in T lymphocyte biology
147. Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm
148. Deletion of the NH2-terminal residue converts monocyte chemotactic protein l from an activator of basophil mediator release to an eosinophil chemoattractant
149. Eosinophil apoptosis is mediated by stimulators of cellular oxidative metabolisms and inhibited by antioxidants: Involvement of a thiol-sensitive redox regulation in eosinophil cell death
150. The chemokine information source: Identification and characterization of novel chemokines using the WorldWideWeb and expressed sequence tag databases
151. Chemokine receptors and their antagonists in allergic lung disease
152. Selectivity and antagonism of chemokine receptors
153. Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils
154. Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration
155. Expression of Th1 and Th2 immunoregulatory cytokines by human eosinophils
156. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type l cytokines (interleukin 2 and interferon gamma): Inhibition by immunoglobulin a complexes
157. 2 integrins
158. Production of macrophage inflammatory protein-1-alpha by human mast cells: Increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability
159. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions
160. Enhanced expression of eotaxin and CCR3 in atopic dermatitis
161. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein
162. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and non-atopic (intrinsic) asthmatics
163. C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: Association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES)
164. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemotactic protein-3 and RANTES in the skin of human atopic subjects: Relationship to eosinophil, T cell, and macrophage recruitment
165. IL-8 is expressed by human peripheral blood eosinophils. Evidence for increased secretion in asthma
166. Subcellular mechanisms of eosinophil degranulation: The role of RANTES, interleukin-5 and tumor necrosis factor-alpha
167. Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: Similar functional responses are accompanied by different morphologic alterations
168. Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and non-atopic control subjects
169. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization
170. Chemokines: A new classification system and their role in immunity